GET DAILY SIGNALSQuantum-Si (QSI) +107% Surge: Proteus Milestones Fuel the Momentum
Key Takeaways
- Quantum-Si (QSI) shares climbed roughly 107% over the last 30 days, rising from $0.795 (Sept. 28 close) to $1.65 (Oct. 27 close).
- The advance was led by Proteus platform milestones, including demonstrated detection of 19 of 20 amino acids announced on Oct. 8, 2026.
- H.C. Wainwright reiterated a Buy rating and a $4.00 price target following the company's interim data at World HUPO 2026.
- The company regained compliance with Nasdaq's minimum bid price requirement in mid-October.
- Over the last quarter, QSI has more than doubled from the low-$0.70s as investor focus shifted to Proteus progress.
- Third-quarter 2026 results are scheduled for Nov. 5, 2026, marking a key near-term catalyst.
Company Background and Positioning
Quantum-Si Incorporated operates from Branford, Connecticut, as a proteomics specialist centered on single-molecule protein sequencing, often called Next-Generation Protein Sequencing (NGPS). Its benchtop system pairs a proprietary semiconductor chip, consumables, and software to enable real-time protein detection and analysis, giving researchers an option beyond conventional mass-spectrometry methods. The commercial lineup focuses on the Platinum and Platinum Pro instruments, while the upcoming Proteus platform is designed to scale up sequencing capacity, precision, and speed substantially.
The company has expanded its production capabilities through partnerships, notably a deepened tie-up with SkyWater Technology (SKYT) for chip manufacturing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Attention centers on Proteus commercialization potential and the transition from technology milestones to actual instrument sales and recurring consumables revenue within the expanding proteomics space.
Recent Stock Performance: 30 Days and the Quarter
Over the past 30 days, QSI shares rose about 107%, moving from a Sept. 28 close of $0.795 to $1.65 on Oct. 27. Trading volume expanded noticeably during the period, with multiple sessions showing well above prior averages as buying interest picked up in early October.
The quarterly view shows comparable strength. Starting from the low-$0.70s in late July, the stock has more than doubled. This re-rating reflects growing attention on Proteus development after earlier worries about launch timing. The path has included volatility with intermittent pullbacks, yet the overall trend across both windows points higher.
Drivers Behind the 30-Day Advance
The 30-day gain stemmed from a sequence of Proteus updates. Interim data presented at the World HUPO 2026 Congress in Singapore on Sept. 28 indicated Proteus produced roughly 30 times more sequencing alignments per run than Platinum Pro, along with a false discovery rate about 4.8 times lower. H.C. Wainwright followed on Sept. 29 by reaffirming its Buy rating and $4.00 price target.
Interest accelerated further on Oct. 8 with the announcement that Proteus had detected 19 of the 20 standard amino acids, and management reiterated the aim of reaching all 20 by year-end 2026. Founder Jonathan Rothberg highlighted the progress publicly as well. On Oct. 15 the company confirmed it had regained compliance with Nasdaq’s minimum bid price rule, easing a listing concern. Together, these elements of scientific progress, analyst backing, and regulatory relief supported the price move.
Quarterly Drivers and Sentiment Shift
Earlier in the quarter, Quantum-Si disclosed a delay in Proteus commercial launch to the second quarter of 2027 along with an approximate 20% workforce reduction expected to deliver around $12 million in annualized cost savings, measures intended to extend a cash runway reported above $230 million. Those steps weighed on the stock initially.
Subsequent milestones, including the HUPO presentation, the 19-amino-acid result, and an expanded Proteus roadshow in the U.S. and Europe, helped reframe the narrative around technology validation and pre-launch engagement. A June collaboration with Cell Signaling Technology to confirm post-translational modification analysis on Proteus added further support. The net effect has been a multi-month upward adjustment in share pricing as the market assesses Proteus prospects.
Near-Term Catalysts to Monitor
Several items stand out for investor attention in the coming weeks. Quantum-Si plans to release third-quarter 2026 results and an update on Nov. 5, 2026, where commentary on Proteus progress and the financial runway should influence views. The company’s target of detecting all 20 amino acids by the end of 2026 remains a notable scientific benchmark ahead of the planned Proteus launch in the second quarter of 2027.
Additional factors include customer uptake and instrument placements, cash burn relative to the runway, competition from established mass-spectrometry players, and any shifts in analyst projections. Coverage remains limited but carries a consensus Buy stance, with an average price target near $2.30 and H.C. Wainwright at $4.00. Outcomes will hinge on execution along the Proteus timeline.
Using AI Tools in My Research Process
I find Tickeron’s AI Trading Bots helpful for spotting automated strategies that align with specific market conditions. The platform offers a range of bots with varying approaches and timeframes, letting users review performance data across different tickers and styles. It serves as a practical way to explore systematic options alongside manual analysis without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
QSI's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for QSI turned positive on October 27, 2026. Looking at past instances where QSI's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on QSI as a result. In 78 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
QSI moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 98 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for QSI moved out of overbought territory on October 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 26 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.004) is normal, around the industry mean (3.837). P/E Ratio (-3.587) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement